Literature DB >> 36186549

Inhalable antibodies for the treatment of COVID-19.

Zhenlin Yang1, Cheng Li2, Yuanlin Song1, Tianlei Ying2, Yanling Wu2.   

Abstract

Entities:  

Year:  2022        PMID： 36186549      PMCID： PMC9509015          DOI： 10.1016/j.xinn.2022.100328

Source DB:  PubMed          Journal:  Innovation (Camb)        ISSN： 2666-6758


× No keyword cloud information.
  5 in total

1.  Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.

Authors:  Sham Nambulli; Yufei Xiang; Natasha L Tilston-Lunel; Linda J Rennick; Zhe Sang; William B Klimstra; Douglas S Reed; Nicholas A Crossland; Yi Shi; W Paul Duprex
Journal:  Sci Adv       Date:  2021-05-26       Impact factor: 14.136

2.  Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.

Authors:  Michael S Piepenbrink; Jun-Gyu Park; Fatai S Oladunni; Ashlesha Deshpande; Madhubanti Basu; Sanghita Sarkar; Andreas Loos; Jennifer Woo; Phillip Lovalenti; Derek Sloan; Chengjin Ye; Kevin Chiem; Christopher W Bates; Reuben E Burch; Nathaniel B Erdmann; Paul A Goepfert; Vu L Truong; Mark R Walter; Luis Martinez-Sobrido; James J Kobie
Journal:  Cell Rep Med       Date:  2021-02-25

3.  Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.

Authors:  Samuel K Lai; Morgan D McSweeney; Raymond J Pickles
Journal:  J Control Release       Date:  2020-12-01       Impact factor: 9.776

4.  Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy.

Authors:  Olga Minenkova; Daniela Santapaola; Ferdinando Maria Milazzo; Anna Maria Anastasi; Gianfranco Battistuzzi; Caterina Chiapparino; Antonio Rosi; Giuseppe Gritti; Gianmaria Borleri; Alessandro Rambaldi; Clélia Dental; Cécile Viollet; Bruno Pagano; Laura Salvini; Emanuele Marra; Laura Luberto; Antonio Rossi; Anna Riccio; Emilio Merlo Pich; Maria Gabriella Santoro; Rita De Santis
Journal:  Mol Ther       Date:  2022-02-12       Impact factor: 12.910

5.  Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.

Authors:  Cheng Li; Wuqiang Zhan; Zhenlin Yang; Chao Tu; Gaowei Hu; Xiang Zhang; Wenping Song; Shujuan Du; Yuanfei Zhu; Keke Huang; Yu Kong; Meng Zhang; Qiyu Mao; Xiaodan Gu; Yi Zhang; Youhua Xie; Qiang Deng; Yuanlin Song; Zhenguo Chen; Lu Lu; Shibo Jiang; Yanling Wu; Lei Sun; Tianlei Ying
Journal:  Cell       Date:  2022-03-10       Impact factor: 66.850
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.